| Filed On | Filing |
|---|---|
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition
Initial clinical data from the Phase 1 healthy-volunteer study of JANX011 to be presented during an investor webcast on November 9, 2026 |
| 06 Aug 2026 |
8-K: Results of Operations and Financial Condition
JANX007 Phase 1b enrollment continues across taxane-naïve monotherapy and darolutamide combination cohorts |
| 23 Jun 2026 |
8-K: Other Events
On June 23, 2026, William Go, M.D., Ph.D. departed as Chief Medical Officer of Janux Therapeutics, Inc. (the "Company") under circumstances that the Company determined to constitute a termination without “Cause” under the terms of the Co... |
| 12 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On June 11, 2026, Janux Therapeutics, Inc. (the “Company”) held the Company’s 2026 Annual Meeting of Stockholders (the “Annual Meeting”). As of April 17, 2026, the record date for the Annual Meeting, 60,961,546 shares of common stock wer... |
| 07 May 2026 |
8-K: Results of Operations and Financial Condition
JANX007 continues to enroll in its Phase 1b taxane-naïve patient population, including combination cohorts with darolutamide |
| 28 Apr 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
In order to achieve a more equal balance of membership among the three classes of directors on the Board of Directors (the “Board”) of Janux Therapeutics, Inc. (the “Company”), the Board determined that one of its members should be recla... |
| 26 Feb 2026 |
8-K: Results of Operations and Financial Condition
Continued clinical execution across TRACTr programs JANX007 and JANX008 |
| 22 Jan 2026 |
8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure
Janux Therapeutics Announces Collaboration and Exclusive Worldwide License Agreement with Bristol Myers Squibb to Develop a Novel Tumor-Activated Therapeutic for Solid Tumors |
| 06 Nov 2025 |
8-K: Results of Operations and Financial Condition
Updates on JANX007 and JANX008 expected in the fourth quarter of 2025 |
| 19 Sep 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
Byron Robinson, Ph.D., previously a named executive officer of Janux Therapeutics, Inc. (the “Company”), ceased to serve as Chief Strategy Officer of the Company and departed from the Company effective September 18, 2025 under circumstan... |
| 07 Aug 2025 |
8-K: Results of Operations and Financial Condition
R&D Day highlighted TRACTr, TRACIr, and ARM pipeline progress and best-in-class potential of novel bispecific ARM platform for autoimmune diseases |
| 13 Jun 2025 |
8-K: Submission of Matters to a Vote of Security Holders
On June 11, 2025, Janux Therapeutics, Inc. (the “Company”) held the Company’s 2025 Annual Meeting of Stockholders (the “Annual Meeting”). As of April 17, 2025, the record date for the Annual Meeting, 59,168,490 shares of common stock wer... |
| 08 May 2025 |
8-K: Results of Operations and Financial Condition
Phase 1b expansion study initiated with JANX007 in taxane-naïve mCRPC patients |
| 27 Feb 2025 |
8-K: Results of Operations and Financial Condition
Recently presented positive Phase 1 clinical trial data for PSMA-TRACTr JANX007 in mCRPC |
| 05 Dec 2024 |
8-K: Other Events
Pre-Funded Warrants to Purchase 238,095 Shares of Common Stock |
| 02 Dec 2024 |
8-K: Regulation FD Disclosure; Other Events
Janux Announces Doses Selected for Phase 1b Expansion Trials Supported by Encouraging Efficacy and Safety Profile Observed in Phase 1a Dose Escalation for JANX007 in mCRPC |
| 06 Nov 2024 |
8-K: Results of Operations and Financial Condition
Enrollment ongoing for PSMA-TRACTr (JANX007) in prostate cancer and EGFR-TRACTr (JANX008) in solid tumors |
| 07 Aug 2024 |
8-K: Results of Operations and Financial Condition
Enrollment ongoing for PSMA-TRACTr (JANX007) in prostate cancer and EGFR-TRACTr (JANX008) in solid tumors |
| 22 Jul 2024 |
8-K: Departure/Election of Directors or Officers; Compensation
The appointment of Eric Dobmeier and Natasha Hernday to the Board brings extensive operational and business development experience to support corporate and pipeline strategy |
| 28 Jun 2024 |
8-K: Submission of Matters to a Vote of Security Holders
On June 26, 2024, Janux Therapeutics, Inc. (the “Company”) held the Company’s 2024 Annual Meeting of Stockholders (the “Annual Meeting”). As of April 29, 2024, the record date for the Annual Meeting, 51,850,667 shares of common stock wer... |
Loading...